Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist / 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 4, 2000, Pages 345-352

  Kreutner, William ^a   Hey, John A ^a   Anthes, John ^a   Barnett, Allen ^a   Young, Simon ^a   Tozzi, Salvatore ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CAS 100643 71 8; CAS 79794 75 5; Claritin ; Desloratadine, antihistaminic activity, preclinical studies; Loratadine

Indexed keywords

DESLORATADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; COMPLIANCE (PHYSICAL); DOSE RESPONSE; DRUG POTENCY; GUINEA PIG; LUNG RESISTANCE; MONKEY; NONHUMAN; PAW EDEMA; RAT; SEDATION;

EID: 0033999939     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300213     Document Type: Article

References (15)

1. [1] Slater, J. W., Zechnich, A. D., Haxby, D. G., Second-generation antihistamines: a comparative review. Drugs 57, 31 (1999)
2. [2] Yap, Y. G., Camm, A. J., The current cardiac safety situation with antihistamines. Clin. Exp. Allergy 29 (Suppl. 1), 15 (1999)
3. [3] Hey, J. A., Affrime, mol/1, Cobert, B. et al., Cardiovascular profile of loratadine. Clin. Exp. Allergy 29 (Suppl. 3), 197 (1999)
4. 1 receptor antagonist. 2nd Communication: Lack of central nervous system and cardiovascular effects. Arzneim.-Forsch./Drug Res. 50 (I), in press (2000)
5. [5] Handley, D. A., McCullough, J. R., Fang, Y. et al., Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine. Ann. Allergy Asthma Immunol. 78,143, Abstr. P164 (1997)
6. [6] Cardelús, I., Puig, J., Bou, J. et al., Xerostomia and mydriasis: two possible muscarinic peripheral side effects associated with descarboethoxyloratadine, the main metabolite of loratadine. Proc. Brit. Pharmacol., 10th-12th December 1997 (Poster P149)
7. 1-antagonist, desethoxycarbonyl-loratadine. J. Allergy Clin. Immunol. 93, 494 (1994)
8. + cells. Clin. Exp. Allergy 27, 559 (1997)
9. 2+ levels and leukotriene release: novel mechanisms of action independent of the anti-histamine activity. Eur. J. Pharmacol. Molecular Pharmacol Section 266, 219 (1994)
10. [10] Berthon, B., Taudou, G., Combettes, L. et al., In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochem. Pharmacol. 47, 789 (1994)
11. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp. Dermatol. 4, 272 (1995)
12. [12] Molet, S., Gösset, P., Lassalle, P. et al., Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin. Exp. Allergy 27, 1167 (1997)
13. [13] Vignola, A. M. Crampette, L., Mondain, M. et al., Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy 50, 200 (1995)
14. [14] Lebel, B., Bousquet, J., Czarlewski, W. et al., Loratadine (L) reduces RANTES release by an epithelial cell line. J. Allergy Clin. Immunol. 99 (Pt. 2), S444, Abstr. 1802 (1997)
15. [15] Cagnoni, F., Mincarini, mol/1, Passalacqua, G. et al., In vitro effects of loratadine and its active metabolite on T lymphocytes. J. Allergy Clin. Immunol. 101 (Pt. 2), 578, Abstr. 331 (1998)